INS and focal segmental glomerulosclerosis: The PPAR-γ agonist rosiglitazone, an antidiabetic drug in the thiazolidinedione class that increases insulin sensitivity in adipocytes, was well tolerated in children with drug-resistant focal segmental glomerulosclerosis (FSGS) in the FONT phase 1 trial.